Media Highlights

Media Highlights

Infection Main Cause of Nonrelapse Deaths With CAR T-Cell Therapy

December 19, 2023

Dr. Jay Spiegel is quoted and identified as a co-author of a study that he presented at ASH 2023. His study showed that CAR T-cell therapy is generally safe even in high-risk patients, but that there remains a significant risk for opportunistic infection, typically early in the post-CAR process.

Read the Full article

Tags:   Sylvester Comprehensive Cancer Center